Soligenix Inc., formerly known as DOR BioPharma Inc., a late-stage biotechnology company, today announced it has formed a consortium to develop technology to enhance acting vaccines, including RiVax, the company’s proprietary vaccine for ricin toxin, which can be used as a biological weapon. Soligenix also announced it was awarded a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to continue this work.

The announced consortium draws together industry and academic researchers from various disciplines, including the University of Colorado, the University of Kansas, and the Tulane National Primate Research Center, SRI International, Health Research Inc, Battelle Memorial Institute, Nanotherapeutics, and BioCon Inc.

“Each of our academic and industry consortium members brings impressive expertise to our vaccine stabilization program,” Dr. Robert N. Brey, PhD, chief scientific officer of Soligenix stated in the press release. “This association has the potential

...

Berkeley HeartLab, a subsidiary of Celera Corporation (NASDAQ:CRA) announced today that they have entered into a collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service launched by Geisinger Health System recently. Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Through this co-marketing agreement, Proven Diagnostics will provide selected diagnostic tools from BHL’s menu of proprietary cardiovascular tests and services which aims at optimizing cardiovascular treatment, these include BHL’s 4myheart cardiovascular disease management program as well.

Proven Diagnostics is a new clinical diagnostic laboratory service provided by Geisinger Health System that is designed to provide medical professionals access to a wide array

...

Berkeley HeartLab, a subsidiary of Celera Corporation (NASDAQ:CRA) announced today that they have entered into a collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service launched by Geisinger Health System recently. Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Through this co-marketing agreement, Proven Diagnostics will provide selected diagnostic tools from BHL’s menu of proprietary cardiovascular tests and services which aims at optimizing cardiovascular treatment, these include BHL’s 4myheart cardiovascular disease management program as well.

Proven Diagnostics is a new clinical diagnostic laboratory service provided by Geisinger Health System that is designed to provide medical professionals access to a wide array of clinical laboratory services. These services include microbiology, biochemical and

...

The procedure has been called “one of the most barbaric mistakes ever perpetrated by mainstream medicine.” Back when medicine was highly primitive, the process involved shoving an ice pick-like instrument between the upper eyelid and the eye in hopes of severing certain nerves of the frontal lobe.

This was the early method of performing a lobotomy. And just 50 years ago, they were carried out not only on severely mentally ill people, but also on moody teenagers, or housewives who’d lost their enthusiasm for domestic work. Seriously. Over 40,000 Americans were lobotomized, often with catastrophic results.

Thankfully, they’re a thing of the past. But it made me think about how medicine has changed over the years and what practices were once acceptable. Just a few hundred years ago, for example, you wouldn’t have questioned the “doctor” for putting leeches on you any more than you do today for prescribing an antibiotic.

What other

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Friday September 25, 2009

DrStockPick.com Stock Report!

CVAT, JNJ, CSRH, MRK, PWRM, MU

**************************************************************

CSRH, Consorteum Holdings Inc, CSRH.OB

CSRH is a company in the financial services, payment and transaction processing industries.

CSRH provides electronic transaction processing and management services to financial institutions, healthcare, government, public and private sector companies. CSRH’s services provide customized, innovative technology solutions that create, augment and enhance customers’ existing financial, payment and transactional processing systems.

CSRH has established an agreement with a third party partner within the payment processing industry to offer Merchant Discount Rates. Consorteum will leverage this new partnership to offer competitive Merchant Discount Rates and Point of

...

DOR BioPharma Inc. is a late-stage biotechnology company that has been gaining national attention for its state-of-the-art technology. DOR reached a major milestone in the advancement of its company with the announcement that it has been awarded a $9.4 million grant from the National Institute of Allergy and Infectious Diseases, which is a division of the National Institute of Health (NIH).

This grant will assist the company’s future over the next five years with the development of formulation and manufacturing processes for vaccines, including RiVax(TM), that are stable at elevated temperatures. The grant will also fund the development of improved thermostable adjuvants expected to result in rapidly acting vaccines that can be given with fewer injections over shorter intervals.

The development of heat-stable vaccines will take advantage of combining several novel formulation processes with well-characterized adjuvants that have been evaluated in numerous vaccine field trials. The formulation and process technology funded

...

Yesterday, ISTA Pharmaceuticals Inc. (ISTA) announced that the U.S. Food and Drug Administration (FDA) approved its drug candidate, Bepreve, for the treatment of ocular itching associated with allergic conjunctivitis in patients two years and above. The drug is approved as a twice-daily prescription eye drop treatment. ISTA filed the New Drug Application for the drug (bepotastine ophthalmic solution) on Nov 13, 2008.  As a reminder, the advisory committee of the FDA had recommended the drug in June. The seven-member panel had voted unanimously in favor of Bepreve after reviewing comprehensive safety and efficacy data from ISTA's clinical program.  Bepreve is expected to be available to ophthalmologists and patients in the United States in the fourth quarter of 2009. The company, which expects to recognize revenues from the drug from this year, is expanding its sales force for this purpose.  ISTA has three drugs on the ...

GenVec, Inc.

(Public, NASDAQ:GNVC)

StocksHaven Investments profiles a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer, and is currently undergoing Phase III trials which are expected to be completed by Q1 2010. In addition to its therapeutic product development programs, GenVec is working with collaborators to develop new applications for its technology through its vaccine development programs. The Company is developing a vaccine in animal health against foot-and-mouth disease and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus, and Herpes Simplex Virus Type 2 (HSV-2). Surrounded by cash infusions through grants, mutual and institutional investors, multi-purpose products with billion dollar market potential, and an already flowing revenue stream – GenVec is one company you shouldn’t pass by.

About

Genvec

...

DrStockPick.com Stock Report!

Thursday August 27, 2009

**************************************************************

Oriental Financial Group Inc. (NYSE: OFG) today announced that its Board of Directors declared a regular quarterly cash dividend of $0.04 per common share for the third quarter ending September 30, 2009, payable on October 15, 2009, to holders of record on September 30, 2009, with an ex-dividend date of September 28, 2009.

Xerox Corporation (NYSE: XRX) has been positioned by Gartner, Inc., in the Leaders Quadrant of the 2009 Magic Quadrant for Managed Print Services (MPS) Worldwide

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that executive management will participate in the Thomas Weisel Partners Healthcare Conference to be held September 9 - 11,

...

ISTA Pharmaceuticals Inc. (ISTA) yesterday announced that its once-per-day eye drug Xibrom QD displayed successful results in a late-stage study. The multi-center, randomized, double-masked, parallel-group study included 299 subjects who underwent cataract operation in one eye.   ISTA revealed that Xibrom QD eye drops were significantly better than placebo at curing eye inflammation 15 days post cataract surgery. The drug was also successful in eliminating eye pain one day following surgery. No serious adverse events were observed and the safety profile appeared to be consistent with the company’s twice a day Xibrom version, which has already hit the market.   The U.S. marketing rights to Xibrom, which is used for the treatment of ocular inflammation following cataract surgery, were acquired by ISTA in 2002 and the product was launched in the U.S. in 2005. As per IMS data, sales in the first half of 2009 were $33.8 million....